Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Transparency In Medical Research And Education
U.S. Senators Mel Martinez (R-FL) and Herb Kohl (D-WI) of the Special Committee on Aging held a hearing to address the issue of transparency in physician-industry financial relationships. Among the hearing"s topics were the industry"s involvement in continuing medical education and its potential use as a method for promoting "off-label" prescribing. The senators heard from witnesses about different ways to achieve balance between appropriate industry involvement in continuing medical education while mitigating unethical and illegal promotion.

Role Of Liver Transplantation Techniques In Surgical Management Of Advanced Renal Urothelial Carcinoma With/without Inferior Vena Cava Thrombus
UroToday.com - Large urothelial carcinoma of the renal pelvis poses a diagnostic as well as surgical challenge to the urologist. This type of malignancy is frequently mistaken preoperatively for renal cell cancer due to its low incidence (10% of all renal malignancies) especially when associated with tumor extension into the inferior vena cava. The presence of a large renal mass should therefore not dissuade the urologist to perform cystoscopy and cytology in order to complete hematuria work-up. Opening the specimen in the operating room will provide clues for the origin of the tumor.
News of the day
Key Event In Prostate Cancer Progression Discovered By Scientists
A study led by researchers at the Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveals how late-stage, hormone-independent prostate tumors gain the ability to grow without need of hormones.
Nutrition

Sepracor Pharmaceuticals Ltd Withdraws Its Marketing Authorisation Application For Lunivia (eszopiclone)

The European Medicines Agency has been formally notified by Sepracor Pharmaceuticals Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Lunivia (eszopiclone), 2 and 3 mg tablets. Lunivia was expected to be used for the treatment of insomnia, including difficulty falling asleep, nocturnal awakening or early awakening in adults, usually for short-term duration. The application for the marketing authorisation for Lunivia was submitted to the Agency on 23 July 2007. In October 2008, Lunivia received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), recommending that the medicine be granted a marketing authorisation. However, the CHMP recommended that the medicine should not be granted "new active substance" status. Following a re÷¬examination procedure at the request of the applicant, the CHMP confirmed its previous opinion in February 2009. At the time of withdrawal, the application was pending the adoption of a marketing authorisation decision by the European Commission. In its official letter, the company stated that the withdrawal of the application was based on the CHMP"s recommendation that Lunivia should not be regarded as containing a new active substance, and that the commercial viability of launching the product in the European Union was compromised. More information about Lunivia and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency"s website after the next CHMP meeting of 26-29 May 2009. Notes 1. Withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage. 2. The press release from the October 2008 meeting can be found here. 3. The summary of the positive opinion from October 2008 can be found here. EMEA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009